Elusive platelet count and limb development gene discovered

New study will enable better antenatal diagnosis for sufferers of rare blood and skeletal disorder

Elusive platelet count and limb development gene discovered

platelet.jpgUniversity of Cambridge
Section of bone marrow showing the megakaryocytes (black arrows), the precursor cells that produce the blood platelets

Researchers have identified an elusive gene responsible for Thrombocytopenia with Absent Radii (TAR), a rare inherited blood and skeletal disorder. As a result, this research is now being transformed into a medical test that allows prenatal diagnosis and genetic counselling in affected families.

The team used genetic sequencing to discover that TAR results from low levels of the protein called Y14. They found that the syndrome occurs by an unique inherited mechanism.

Platelets are the second most abundant cell in the blood. Their main task is to survey the blood vessel wall for damage and to plug and repair it where required. Some people are born with low numbers of platelets and these rare conditions are thought to be inherited. TAR syndrome combines the unique features of low platelet count and prominent bleeding, especially in infancy, and skeletal abnormalities affecting the upper limb ranging from absence of the radial bone in the forearm to virtually total absence of upper limb. The genetic basis of TAR syndrome has eluded researchers for 50 years.

"Without the use of modern genomics technologies, the discovery of this unexpected mechanism of disease inheritance would have been much more difficult. To achieve our latest findings, we deciphered about 40 million letters of genetic code in five patients."

Dr Cornelis Albers, from the Sanger Institute and the University of Cambridge

Many people with TAR were known to have a deletion in one copy of chromosome 1, but this was thought not to be the whole story because parents who carry the same deletion are not suffering from TAR: other variants had to be involved. The team sequenced the genomes of people affected by the disorder who also carried the deletion and discovered that the vast majority of them had one of two variants of a gene called RBM8A. They found that when the genetic deletion and one of the variants are co-inherited by a child, TAR results.

RBM8A controls the production of the protein Y14. They found that the combination of the genetic deletion of one copy of the RBM8A gene and the variants on the other copy greatly reduces the level of Y14. The team concluded that it is low levels of Y14 that affect platelet formation and cause TAR disorder.

"The lack of production of adequate amounts of the protein Y14 in TAR patients only seems to effect the formation of platelets but not of other blood cells. We have shed some light on how some inherited disorders can present with such striking features associating seemingly unconnected characteristics such as skeletal and blood defects."

Dr Cedric Ghevaert from the University of Cambridge

This is the first human disorder identified to be caused by a presumed defect of the Exon Junction Complex, part of the cellular machinery that contributes to producing messages that direct protein production. This study opens the path that could lead to the identification of the genetic basis of other similar inherited syndromes, which will help improvements in diagnosis, genetic counselling and patient care in the NHS and beyond.

"The discovery of the gene for TAR will make it simpler to diagnose more accurately future cases with a simple DNA test. This new test is currently being developed for the NHS as part of the international ThromboGenomics initiative led by Professor Ouwehand."

Dr Ruth Newbury-Ecob, Honorary Reader in Medical Genetics and Consultant in Clinical Genetics at the University of Bristol Hospitals

Notes to Editors
Publications
  • Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome.

    Albers CA, Paul DS, Schulze H, Freson K, Stephens JC et al.

    Nature genetics 2012;44;4;435-9, S1-2

The findings were made following a collaborative study by the NHS Blood and Transplant platelet research team at the University of Cambridge and the Wellcome Trust Sanger Institute, which is led by Dr Cedric Ghevaert and Professor Willem Ouwehand. The Cambridge researchers joined forces with Dr Ruth Newbury-Ecob from the University of Bristol and worked together with various other European research partners from Belgium, France, Germany and the Netherlands.

Funding

The platelet research team in Cambridge is supported by the British Heart Foundation, the European Commission, the National Institute for Health Research for England (NIHR), NHS Blood and Transplant and the Wellcome Trust.

Selected Websites
Contact the Press Office

Emily Mobley, Media Manager

Tel +44 (0)1223 496 851

Dr Samantha Wynne, Media Officer

Tel +44 (0)1223 492 368

Dr Matthew Midgley, Media Officer

Tel +44 (0)1223 494 856

Wellcome Sanger Institute,
Hinxton,
Cambridgeshire,
CB10 1SA,
UK

Mobile +44 (0) 7748 379849

Recent News

Malaria control success in Africa at risk from spread of multi-drug resistance
Regional populations of Plasmodium falciparum parasites in Africa are sharing genetic material in all directions – including genes that can confer resistance to anti-malarial drugs
Map of malaria behaviour set to revolutionise research
The Malaria Cell Atlas gives the highest resolution view of malaria parasite gene expression to date and monitors how individual parasites change as they develop in both the mosquito and human host
Diarrhoea-causing bacteria adapted to spread in hospitals
Gut-infecting bacterium Clostridium difficile is evolving into two separate species, with one group highly adapted to spread in hospitals